Wednesday November 20
SOURCE: Biophan Technologies, Inc.
BIOPHAN TECHNOLOGIES LISTS ON FRANKFURT STOCK EXCHANGE
Rochester, NY (November 20, 2003) – Biophan Technologies, Inc. (OTCBB: BIPH) is pleased to announce that its common stock has been accepted for listing and trading on the Frankfurt Stock Exchange, commencing November 18, 2003.
“Listing on the Frankfurt Exchange should increase the profile of Biophan with both private and institutional investors in Germany and across Europe and as we continue to develop and commercialize our technology platform,” stated Biophan’s CEO, Michael Weiner.
Biophan, based in Rochester, New York, develops and markets technology to enable biomedical devices both for interventional medicine (guidewires, catheters, endoscopes, et al), and implantable devices such as pacemakers, defibrillators, neurostimulators, implantable drug pumps, and others medical devices, to be safe and compatible with magnetic resonance imaging (MRI). For more information, please visit
www.biophan.com.The Frankfurt Stock Exchange (FWB) is the largest of the eight Germany stock exchanges. It ranks third in the world behind the NYSE and NASDAQ. The FWB is operated by Deutsche Borse AG. For more information, visit the Frankfurt Stock Exchange at:
deutsche-boerse.com. Biophan’s trading symbol on the XETRA (Electronic Dealing System) is BTN and the German securities code (WKN) is
541861.
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan’s MRI technologies; the approval of Biophan’s patent applications; the successful implementation of Biophan’s research and development programs; the acceptance by the market of Biophan’s products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Biophan’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Press Inquiries
Michael Weiner, Chief Executive Officer
Biophan Technologies, Inc.
585-214-2441
mike@biophan.com
Investor/Shareholder Inquiries:
Racquel Rivera, VP
Trilogy Capital Partners, Inc.
(800) 330-6540
racquel@trilogy-capital.com